NephrologyOnline.net

Nephrology Xagena

Clear cell renal cell carcinoma ( ccRCC ) is well known for its hypervascularity due to the Von Hippel-Lindau/hypoxia-inducible factor dysregulation. Recent findings suggested that copper transporte ...


Top-line results from the CABOSUN randomized phase 2 trial of Cabozantinib ( Cabometyx; Cometriq ) in patients with previously untreated advanced renal cell carcinoma ( RCC ) were announced. The tria ...


Lenvatinib mesylate ( Lenvima ) is an orally administered multiple receptor tyrosine kinase ( RTK ) inhibitor with a novel binding mode that selectively inhibits the kinase activities of vascular endo ...


Pulmonary arterial hypertension ( PAH ) is a major complication in renal failure patients, but very little information is available on the cardiovascular parameters in these patients. The prevalence ...


The FDA ( Food and Drug Administration ) has required labeling changes regarding the recommendations for Metformin-containing medicines for diabetes to expand Metformin’s use in certain patients with ...


Death in dialysis patients results mainly from cardiovascular and cerebrovascular diseases. No prospective study has compared the rates of mortality or cardiovascular events between patients with and ...


The aim of a study was to compare survival of resected and unresected patients in a large cohort of patients with metastases to the pancreas from renal cell carcinoma ( PM-RCC ). Data from 16 Itali ...


Patients with metastatic renal cell carcinoma ( mRCC ) received Sunitinib ( Sutent ) in a global expanded-access program ( EAP ). Researchers have reported the efficacy and safety results for the ...


Aim of a study was to investigate for the presence of existing prognostic factors in patients with bone metastases ( BMs ) from renal cell carcinoma ( RCC ) since bone represents an unfavorable site o ...


Nivolumab ( Opdivo ), an anti-PD-1 immune checkpoint inhibitor, significantly prolongs survival in patients with advanced kidney cancer, whose disease has progressed after their first treatment, accor ...


Although assessment of cardiovascular safety is mandated by regulatory agencies for the development of new drugs to treat type 2 diabetes mellitus, evaluation of their renal safety has been relatively ...


Limited prospective data are available on the long-term safety of Darbepoetin alfa ( Aranesp ) for treating anemia in children with chronic kidney disease ( CKD ). In this prospective, phase IV, ob ...


Safety concerns with erythropoietin analogues and intravenous ( IV ) iron for treatment of anemia in chronic kidney disease ( CKD ) necessitate development of safer therapies. Roxadustat ( FG-4592 ...


The TEMPO 3:4 Trial results suggested that Tolvaptan ( Samsca ) had no effect compared with placebo on albuminuria in autosomal-dominant polycystic kidney disease ( ADPKD ) patients. However, the use ...


The association between apparent treatment resistant hypertension ( ATRH ) and clinical outcomes is not well studied in chronic kidney disease. Researchers have analyzed data on 3367 hypertensive ...